Pricing: Paid
Verified: Yes
Rating: 4.2/5
Neurotechnology company developing an implantable brain-computer interface for people with paralysis to control devices through neural signals.
Some links may be affiliate links. We may earn a small commission at no extra cost to you. Learn more
Category
Assistive technology (AT)
Verified Selection
Updated Recently
Community Reviewed
Pricing
Neuralink is not commercially available for general purchase. The device is currently being studied in a clinical trial (the PRIME Study) with a specific enrollment process. Commercial pricing and availability have not been announced.
| Plan | Details |
|---|---|
| Free | |
| Paid | Neuralink's N1 device is currently available only through participation in the PRIME Study clinical trial, which has specific medical eligibility requirements. Commercial pricing has not been announced. |
What is Neuralink?
Quick Summary
Neuralink is a neurotechnology company founded by Elon Musk that is developing an implantable brain-computer interface device designed to enable people with paralysis and other severe motor disabilities to control computers, communication devices, and assistive technology directly through neural signals. The company is currently conducting its first-in-human clinical trial, known as the PRIME Study, which received FDA Breakthrough Device designation. Neuralink's device is not commercially available for general purchase and is in active research and clinical development.
Neuralink is developing an implantable brain-computer interface (BCI) system that records neural signals from the brain and translates them into digital commands for controlling external devices. The implanted chip, called N1, is placed in the motor cortex region of the brain by a precision surgical robot and communicates wirelessly with external software. Early clinical trial participants have demonstrated the ability to control a computer cursor, type text, and interact with software applications using neural signals alone, without any physical movement required. The system is designed to function continuously and recharge wirelessly without external connections. Neuralink's current clinical work is focused on individuals with quadriplegia, ALS, and other conditions causing severe motor impairment who have no functional use of their limbs and cannot communicate or interact with technology through standard input methods. The PRIME Study, which received FDA Breakthrough Device designation, is evaluating the safety and initial efficacy of the N1 device in this patient population. Participants in the trial use the BCI to control computers for communication, web browsing, and digital productivity. Explore this option. Neuralink's longer-term research roadmap includes restoring vision through a separate device called Blindsight and expanding the range of conditions the technology addresses. As of the current clinical phase, Neuralink is not available for commercial purchase. Participation in the PRIME Study requires meeting specific medical eligibility criteria and going through a formal enrollment process. The device involves an irreversible surgical implantation procedure with inherent medical risks, and long-term safety data is still being gathered through ongoing trials. Regulatory approval for broader commercial use in any jurisdiction has not been announced as of the current clinical stage. Prospective participants or their caregivers can express interest through the Neuralink website's patient registry Browse related picks.
Associated Tags
brain-computer interface, neural implant, assistive technology, paralysis technology, neurotechnology
Key Features
Implantable N1 neural signal recording chip
Wireless communication with external devices
Computer cursor and text control via neural signals
Wireless battery recharging without external connections
Surgical implantation by precision robotic system
FDA Breakthrough Device designation for PRIME Study
Real Use Cases
How professionals leverage Neuralink – Implantable Brain-Computer Interface for Paralysis and Disability
- Enabling individuals with quadriplegia to control a computer cursor and type text using neural signals without physical movement
- Providing people with ALS a communication interface that does not require physical motor function
- Allowing individuals with severe motor impairment to interact with smartphones and digital applications independently
- Researching the safety and efficacy of implantable BCI technology through the PRIME Study clinical trial
- Exploring neural signal decoding for computer control in individuals with otherwise complete motor paralysis
Editor's Verdict
Official ReviewNeuralink represents a significant research-stage brain-computer interface with demonstrated early clinical results in individuals with paralysis, backed by FDA Breakthrough Device designation for its ongoing PRIME Study. The device is not commercially available, requires surgical implantation, and is accessible only through clinical trial enrollment with specific medical eligibility requirements.
4.2 / 5.0
Editor RatingReviewed by Sohail Akhtar
Lead Editor & Founder
Pros
What we like
- Wireless neural recording and device control removes the need for physical movement entirely, which has meaningful implications for individuals with complete motor paralysis who currently have no digital input options
- FDA Breakthrough Device designation for the PRIME Study reflects formal regulatory recognition of the device's potential to address a serious unmet medical need
- Wireless recharging and communication design eliminates percutaneous (through-skin) cables, which reduces infection risk compared to earlier external BCI systems
Cons
Limitations
- Neuralink's device requires irreversible surgical brain implantation, which carries inherent medical risks; long-term safety data is still being collected through the ongoing PRIME Study
- The technology is currently accessible only through a specific clinical trial with strict eligibility criteria, and no commercial availability or regulatory approval for broad market use has been announced
Target Audience
Who should use Neuralink?
Individuals with quadriplegia, ALS, or severe motor impairment who meet PRIME Study enrollment criteriaNeuroscience and neurotechnology researchers studying brain-computer interface capabilitiesHealthcare professionals working in spinal cord injury and motor neuron diseaseAssistive technology advocates and institutions following BCI clinical developmentCaregivers and clinical coordinators supporting individuals exploring BCI trial participation
Top Alternatives
Dedicated alternatives page →Free
Goblin Tools
Free collection of single-purpose AI tools designed for neurodivergent users, covering task breakdown, tone analysis, time estimation, and daily organization.
Paid
Atom Limbs
Non-invasive AI-powered bionic arm prosthetic by Atom Bodies using EMG sensors and machine learning for individual finger control, haptic grip feedback, and all-day wear comfort.
Free Trial
ElevenLabs Reader
ElevenLabs mobile and web app that converts articles, PDFs, ePubs, and web pages into natural AI-narrated audio, with 10 free hours per month and unlimited access on the Ultra plan.
Free
TTS Reader
Free browser-based text-to-speech tool that reads any text, document, or web page aloud via Chrome extension.
Frequently Asked Questions
What is Neuralink?
Neuralink is a neurotechnology company developing an implantable brain-computer interface called the N1 chip, which translates neural signals into digital commands for controlling computers and devices.
Is Neuralink commercially available?
No—Neuralink is currently in clinical trials through the PRIME Study and is not commercially available for general purchase. Enrollment requires meeting specific medical eligibility criteria.
Who is Neuralink designed for?
Neuralink's current clinical work targets individuals with quadriplegia, ALS, and other conditions causing severe motor impairment who cannot interact with technology through standard physical input.
How does the Neuralink device work?
The N1 chip is surgically implanted in the motor cortex and records neural signals, which are wirelessly transmitted to software that translates them into computer commands such as cursor movement and typing.
Has Neuralink received FDA approval?
The Neuralink PRIME Study has received FDA Breakthrough Device designation. This designation expedites development and review but does not constitute commercial approval.